What Happened
Hims & Hers Health, a telehealth company, reported mixed financial results for the last quarter of 2025, with earnings per share of $0.08, surpassing analysts’ expectations of $0.04. Revenue reached $617.8 million, slightly below the anticipated $619 million. The company also provided a lukewarm guidance for the full year of 2026, projecting revenue between $2.7 billion and $2.9 billion, which is in line with analysts’ expectations of $2.74 billion.
However, the company is currently facing significant legal challenges, including a patent infringement lawsuit from Novo Nordisk regarding its recently launched copy of the Wegovy weight loss pill. This legal trouble has contributed to a decline in Hims stock, which has fallen over 50% since the beginning of the year, with more than 30% of that drop occurring after the announcement of the Wegovy copy.
Why It Matters
The mixed financial performance and legal issues highlight the precarious position of Hims & Hers in the competitive telehealth market. While the company has seen growth in its customer base, reaching 2.51 million subscribers, the ongoing legal battles could hinder its expansion plans and impact investor confidence. The stock’s decline following the earnings report indicates market concerns regarding the company’s future profitability and operational stability.
What’s Next
Looking ahead, Hims & Hers is expected to focus on expanding its treatment offerings while navigating the legal landscape surrounding its Wegovy copy. The company has projected an adjusted EBITDA between $300 million and $375 million for 2026, which falls short of analysts’ expectations of $369 million. Investors will be closely monitoring the company’s ability to resolve its legal challenges and meet its financial guidance in the upcoming quarters.
